The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Open accessAbstract
Aims The severe acute respiratory syndrome coronavirus 2, better known as COVID-19 has become the current health concern to the entire world. Initially appeared in Wuhan, China around December 2019, it had spread to almost 187 countries due to its high contagious nature. Precautionary measures remain the sole obliging tactic to cease the person to person transmissions till any effective method of treatment or vaccine is developed. Amidst the pandemic, research and development of new molecule is labour-intensive and tedious process. Drug repurposing is the concept of identifying therapeutically potent molecule from the library of pre-existing molecules. Materials and methods In the present study, 61 molecules that are already being used in clinics or under clinical scrutiny as antiviral agents are surveyed via docking study. Docking study was performed using Maestro interface (Schrödinger Suite, LLC, NY). Key findings Out of these 61 molecules, 37 molecules were found to interact with >2 protein structures of COVID-19. The docking results indicate that amongst the reported molecules, HIV protease inhibitors and RNA-dependent RNA polymerase inhibitors showed promising features of binding to COVID-19 enzyme. Along with these, Methisazone an inhibitor of protein synthesis, CGP42112A an angiotensin AT2 receptor agonist and ABT450 an inhibitor of the non-structural protein 3-4A might become convenient treatment option as well against COVID-19. Significance The drug repurposing approach provide an insight about the therapeutics that might be helpful in treating corona virus disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Sohrabi, C., Alsafi, Z., O'Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., Iosifidis, C., & Agha, R. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.02.034 · Cited by 6,069
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
Rothan, H. A., & Byrareddy, S. N. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102433 · Cited by 5,840
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030644s · Cited by 5,177
Baig, A. M., Khaleeq, A., Ali, U., & Syeda, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00122 · Cited by 2,207
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Devaux, C. A., Rolain, J.-M., Colson, P., & Raoult, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105938 · Cited by 1,099
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117592 · Cited by 923
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
Choy, K.-T., Wong, A. Y.-L., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P.-H., Huang, X., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104786 · Cited by 922
Bogoch, I. I., Watts, A., Thomas-Bachli, A., Huber, C., Kraemer, M. U. G., & Khan, K. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa008 · Cited by 898
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715
Zhang, L., & Zhou, R. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c04198 · Cited by 163
Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds
Huang, H., Zhang, G., Zhou, Y., Lin, C., Chen, S., Lin, Y., Mai, S., & Huang, Z. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00138 · Cited by 161
Vijayakumar, S., Palani, M., Prabhu, S., & Singh, R. A. S. (2017) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2017.07.006 · Cited by 93
Bryan-Marrugo, O. L., Ramos‐Jiménez, J., Barrera-Saldaña, H. A., Rojas‐Martínez, A., Vidaltamayo, R., & Rivas, A. (2015) · Medicina Universitaria · doi:10.1016/j.rmu.2015.05.003 · Cited by 59
Carlesso, A., Chintha, C., Gorman, A. M., Samali, A., & Eriksson, L. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-39939-z · Cited by 42
Jasuja, H., Chadha, N., Kaur, M., & Silakari, O. (2014) · Molecular Diversity · doi:10.1007/s11030-013-9497-z · Cited by 35
Pradeep, H., & Rajanikant, G. K. (2012) · Molecular Diversity · doi:10.1007/s11030-012-9387-9 · Cited by 20
Bhuvaneshwari, S., & Sankaranarayanan, K. (2019) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2019.1566172 · Cited by 12
Cited by
DeepPurpose: a deep learning library for drug–target interaction prediction
Huang, K., Fu, T., Glass, L. M., Zitnik, M., Xiao, C., & Sun, J. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa1005 · Cited by 484
Drug repurposing approach to fight COVID-19
Singh, T. U., Parida, S., Lingaraju, M. C., Kesavan, M., Kumar, D., & Singh, R. K. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00155-6 · Cited by 480
Metadata
- Authors
- Shah, B., Modi, P., & Sagar, S. R.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 252
- Pages
- 117652
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3015741518
- Cited by
- 401
- References
- 21
- FWCI
- 41.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.